Healx Ltd. news
Despite affecting over 400 million people around the globe, rare diseases have largely been overlooked by traditional drug discovery methods. This is because traditional model often prioritise disease areas where there is a greater understanding of the basic underlying biology and which, in turn, generally come from the larger patient populations associated with more common diseases. This is part of the reason why
Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, is proud to announce that world-renowned computational drug discovery expert, Nathan Brown, has joined the team as Director of Digital Chemistry.
Nathan joins from BenevolentAI, where he led the Cheminformatics team and was responsible for the research and development of new and effective approaches for computational drug design. Globally
Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, today announced an exciting partnership with Ono Pharmaceutical Co., Ltd., one of Japan’s largest pharmaceutical companies and a global leader in the field of R&D-orientated drug discovery. The collaboration will leverage Healx’s innovative indication expansion technology to iden
Experienced machine learning and engineering leader Andrew Watson joins Healx from technology giant Dyson as VP of Artificial Intelligence. In his new role, Andrew will deepen the investment in Healx’s artificial intelligence team and scale Healx’s technical capabilities in order to identify and progress more novel treatments for rare diseases. Andrew’s appointment reinforces Healx’s commitment to technical excellence and AI innovation. It follows the senior appointmen